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Abstract
Crimean-Congo hemorrhagic fever orthonairovirus (CCHFV) is one of the most widespread
medically important arboviruses, causing human infections that result in mortality rates of up
to 60%. We describe the selection of a high-affinity small protein (Affimer-NP) that binds
specifically to the nucleoprotein (NP) of CCHFV. We demonstrate the interference of Affi-
mer-NP in the RNA-binding function of CCHFV NP using fluorescence anisotropy, and its
inhibitory effects on CCHFV gene expression in mammalian cells using a mini-genome sys-
tem. Solution of the crystallographic structure of the complex formed by these two molecules
at 2.84 Å resolution revealed the structural basis for this interference, with the Affimer-NP
binding site positioned at the critical NP oligomerization interface. Finally, we validate the in
vitro application of Affimer-NP for the development of enzyme-linked immunosorbent and
lateral flow assays, presenting the first published point-of-care format test able to detect
recombinant CCHFV NP in spiked human and animal sera.
Author summary
Crimean-Congo hemorrhagic fever virus (CCHFV) is one of the most lethal human path-
ogens in existence. No approved vaccine or therapies exist and rapid diagnosis of CCHFV
is a critical aspect of disease management. We describe the selection and characterization
of a high affinity non-antibody binding protein, Affimer-NP, that specifically recognises
the CCHFV nucleocapsid protein (NP). Affimer-NP interferes with the RNA-binding
function of CCHFV NP and inhibits CCHFV gene expression in mammalian cells.
PLOS NEGLECTED TROPICAL DISEASES
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008364 June 3, 2020 1 / 20
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: A´lvarez-Rodrı´guez B, Tiede C, Hoste ACR,
Surtees RA, Trinh CH, Slack GS, et al. (2020)
Characterization and applications of a Crimean-
Congo hemorrhagic fever virus nucleoprotein-
specific Affimer: Inhibitory effects in viral
replication and development of colorimetric
diagnostic tests. PLoS Negl Trop Dis 14(6):
e0008364. https://doi.org/10.1371/journal.
pntd.0008364
Editor: Brian Bird, School of Veterinary Medicine
University of California Davis, UNITED STATES
Received: February 19, 2020
Accepted: May 5, 2020
Published: June 3, 2020
Copyright: © 2020 A´lvarez-Rodrı´guez et al. This is
an open access article distributed under the terms
of the Creative Commons Attribution License,
which permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All PDB files are
available from the PDB database (PDB ID: 6Z0O,
https://www.rcsb.org/structure/unreleased/6Z0O).
Funding: This work was supported by an EU Marie
Skłodowska-Curie Actions (MSCA, ec.europa.eu)
Innovative Training Network (ITN): H2020- MSCA-
ITN-2016, under grant No 721367 (to B. A´lvarez-
Rodrı´guez). The funders had no role in study
Solution of the crystallographic structure of the CCHFV NP/Affimer-NP complex at 2.84
Å resolution revealed the structural basis for this interference, and we validated the in
vitro application of this novel molecule for the development of ELISA and lateral flow
assays, presenting the first published prototype point-of-care test able to detect recombi-
nant CCHFV NP in spiked human and animal sera. These findings present a possible
starting point for the future development of anti-viral molecules targeted to CCHFV NP,
and diagnostic assays for the detection of CCHFV NP, contributing to the preparedness
for potential future outbreak scenarios.
Introduction
Crimean-Congo hemorrhagic fever orthonairovirus (CCHFV) is an emerging arbovirus that
causes serious human disease characterized by an acute febrile illness with frequent progres-
sion to hemorrhagic fever [1]. CCHFV outbreaks can result in alarming mortality rates of up
to 80% in hospital settings [2]. The incidence of CCHFV-mediated disease closely matches the
geographical range of its Hyalomma tick host, which is widespread throughout Africa, Asia,
and Southern Europe [3]. As such, CCHFV is the most widespread tick-borne virus on earth
[3,4].
CCHFV is classified within the Nairoviridae family of the order Bunyavirales [5]. Its
genome comprises three negative sense RNA segments named small (S), medium (M) and
large (L), which respectively encode the nucleoprotein (NP), that encapsidates each RNA seg-
ment; the glycoprotein precursor, which is post-translationally cleaved to yield envelope glyco-
proteins Gn and Gc; and the L protein that contains both RNA-dependent RNA polymerase
(RdRp) and OTU-like modules, with the latter performing immunomodulatory roles. The
RdRp and NP associate with the segments forming ribonucleoproteins (RNPs) [6] that act as
templates for all viral RNA synthesis activities. The structure of native viral RNPs has not been
elucidated, but crystal structures of recombinant CCHFV NP [7–9] have revealed possible resi-
dues involved in RNA-binding and NP-NP interactions, validated using reconstituted mini-
genome systems [10].
Due to its high pathogenicity and lack of efficacious treatments, CCHFV is a prioritized
pathogen, with an urgent need for accelerated research in disease diagnosis and treatment
[11]. Differential diagnosis during the early disease phase is difficult due to associated non-spe-
cific febrile symptoms. RT-PCR methods are the current gold standard for detection of
CCHFV during the viremic phase, offering sensitive and highly specific results [12]. An anti-
gen-detection ELISA test (VectoCrimea-CHF-antigen, VectorBest) is commercially available,
but most available immunoassays are based on detection of CCHFV-specific IgG or IgM [13–
17]. Such tests are normally used in animal serosurveys [16,18] or during late phases of disease
but, in severe patients cases, the production of antibodies is normally delayed, low, or even
absent [19].
Late diagnosis decreases treatment efficacy and increases the risk of fatal outcomes and nos-
ocomial spread [20], making quick and accurate detection of antigen important for disease
management. In addition, fatal outcome is associated with higher viral loads [21,22]. For these
reasons, the development of a point-of-care test that enables early and rapid detection of
CCHFV antigen in remote areas or low-resource settings is an urgent and unmet need [23].
Here, we describe the selection of a high-affinity small protein (Affimer-NP) that binds spe-
cifically to CCHFV NP and blocks both its RNA-binding function and ability to support gene
expression. The crystal structure of Affimer-NP bound to CCHFV NP revealed the interaction
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contacts between these two molecules, explaining these interference characteristics. In addi-
tion, we validated the use of Affimer-NP for the development of ELISA and lateral flow tests
that detected CCHFV NP in human and animal spiked sera.
Methods
Production of bunyaviral nucleoproteins
CCHFV, Hazara virus (HAZV), Schmallenberg virus (SBV) and Rift Valley fever virus
(RVFV) NPs were expressed in bacteria and purified as previously described [10,24].
Generation of anti-CCHFV NP IgGs
CCHFV NP was lyophilized using an AdVantage 2.0 Lyophilizer (SP Scientific) and used as
immunogen (GenScript). Rabbit polyclonal IgGs were purified by Protein A affinity
chromatography.
Screening for CCHFV NP-binding Affimers
Affimer screening was performed as previously described [25], using CCHFV NP as target.
ORFs of unique binders were subcloned into pET11a expression vector for production of the
corresponding Affimers appended with an N-terminal 8x his tag and cysteine for downstream
functionalization using bacterial expression (E. coli strain Rosetta 2), and purified using Ni2
+-NTA affinity chromatography as previously described [26].
Affimers biotinylation
Immobilized TCEP disulphide reducing gel (Thermo-Fisher) was used to reduce Affimer dis-
ulphide bonds according to manufacturer’s instructions. For biotin labelling, 6 μL of biotin
maleimide in DMSO (5 mg/mL) were added to reduced Affimers (0.5 mg/mL) and incubated
at RT for 2 h. Zeba spin desalting columns (7 kDa MWCO, Thermo-Fisher) were used to
remove free biotin.
Pull-down assays
Dynabeads MyOne Streptavidin T1 (Thermo-Fisher) were blocked overnight with casein
blocking buffer (Sigma-Aldrich). After washing, beads were incubated with 2 μg of biotiny-
lated Affimer for 1 h at RT. After further washing, beads were incubated with 10 μg of target
molecule and pull-down assays were performed using a KingFisher Flex System (Thermo-
Fisher). Samples were heated for 5 min at 95˚C, beads pelleted at 13,000 rpm and removed
using a magnetic rack.
ELISA to check biotinylation of Affimers
Briefly, serial dilutions of biotinylated Affimers in PBS were added to Nunc-Immuno Maxi-
Sorp strips (Thermo Scientific) and incubated overnight at 4˚C. After washing with PBS-T,
250 μL of blocking buffer (Casein Blocking Buffer 10x, Sigma-Aldrich) were added and strips
were incubated at 37˚C for 3 h. Strips were washed with PBS-T and streptavidin-HRP in block-
ing buffer was added. After incubation for 1h at RT on a vibrating platform shaker, wells were
washed with PBS-T and 50 μL of TMB (SeramunBlau fast TMB substrate solution, Seramun)
were added. Absorbance at 620 nm was measured after 5 min with a plate reader (TECAN).
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Western blotting
Proteins were transferred to polyvinylidene fluoride (PVDF) membranes (Millipore) using a
Trans-Blot semi-dry cell (Bio-Rad) in Towbin for 1 h at 15 V. Membranes were blocked over-
night at 4˚C in 50% Odyssey blocking buffer (LI-COR) in PBS, then incubated with primary
antibody (anti-CCHFV NP IgGs/anti-his-tag mouse IgGs Alexa Fluor-647) for 1 h at RT.
Membranes were washed and incubated with anti-rabbit-IRDye 800CW (LI-COR). Fluores-
cent signal was visualized using an Odyssey Sa Infrared Imaging System (LI-COR).
Surface Plasmon Resonance
Biotinylated Affimers were immobilized on a Sensor Chip SA (GE Healthcare) via streptavi-
din-biotin interaction using a Biacore 3000 (GE Healthcare). Affimers were diluted in PBS
(100 nM) and injected into their respective flow cells at 5 μL/min until surface density reached
100 response units. A flow cell was left empty as reference surface. CCHFV and HAZV NPs
diluted in PBS at different concentrations were injected at 20 μL/min for 120 seconds. BIAeva-
luation software was used for double-referencing analysis. Affinity and kinetic constants were
calculated using a Langmuir 1:1 binding model and steady-state affinity models.
Circular Dichroism
Protein samples were dialyzed in PBS using a Pur-A-Lyzer Dialysis Kit, MWCO 6–8 kDa
(Sigma-Aldrich) and a 1:1 molar mixture of CCHFV NP:Affimer-NP was prepared. Samples
were transferred to 1 mm path-length quartz cuvettes. A PBS-only sample was included as ref-
erence. Thermal melts were performed in a Chirascan Plus Spectometer (Applied Photophy-
sics) monitoring ellipticity at 190–260 nm between 20˚C to 90˚C at 1˚C/min. Ellipticity values
(mdeg) were normalized to mean molar ellipticity per residue (MRE). Thermal data was ana-
lysed using Global3 (Applied Photophysics), and secondary structure content predicted using
BeStSel [14].
Large scale expression and purification of the Affimer-NP/CCHFV NP
complex
Plasmid sequences and detailed cloning strategies are available upon request. Affimer-NP
ORF was subcloned into a pETSUMO bacterial expression vector (pETSUMO-Affimer-NP).
Rosetta 2 (DE3) E. coli cells were transformed with pET-SUMO-Affimer-NP and used to inoc-
ulate LB medium containing kanamycin (50 mg/mL). Cell cultures were grown at 37˚C and
induced by addition of Isopropyl β-D-1-thiogalactopyranoside (IPTG) at 500 mM, followed by
further shaking at 18˚C for 16 h. Cells were pelleted and resuspended in lysis buffer (500 mM
NaCl, 50 mM NaH2PO4 pH 7.4, 20 mM imidazole, 0.1% Triton X-100, 1 mM MgCl2, 1 mg/
mL lysozyme (Sigma-Aldrich), a complete protease inhibitor cocktail tablet EDTA-free
(Roche), 1 U DNase I/1 L culture, 1 U RNase). Cells were sonicated using a Soniprep 150, after
which soluble and insoluble fractions were separated by centrifugation at 45,000 xg for 30 min.
Purification involved a first column affinity chromatography step using Super Ni2+-NTA
(Generon) equilibrated with binding buffer (500 mM NaCl, 50 mM NaH2PO4 pH 7.4, 20 mM
imidazole). Soluble bacterial lysate was applied to column, washed with binding buffer with
increasing concentrations of imidazole, after which 6xhis-SUMO-Affimer-NP was eluted with
elution buffer (500 mM NaCl, 50 mM NaH2PO4 pH 7.4, and 300 mM imidazole). The elution
fractions were dialyzed to remove excess imidazole and a total of 0.5 mg of 6xhis-SUMO prote-
ase Ulp1 produced in-house was added for every 10 mg of eluted 6xhis-SUMO-Affimer-NP.
The mixture was transferred to 10 kDa MWCO dialysis tubing (Thermo Scientific) and
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dialyzed for 16 hr at 4˚C in dialysis buffer (500 mM NaCl, 50 mM NaH2PO4 pH 7.4). The dia-
lyzed protein was subjected to a second Ni2+-NTA affinity chromatography step, and the flow-
through containing native Affimer-NP was collected and concentrated to 5 mL using centrifu-
gal filters (Amicon Ultra 15 10 kDa MWCO regenerated cellulose). The sample was injected
into an equilibrated HiLoad 26/600 Superdex 75 pg (GE Healthcare) column using an Akta
prime at 0.5 mL/min at 4˚C and 3 mL fractions were collected, after which the purity of Affi-
mer-NP in eluted fractions was analyzed by SDS-PAGE and Coomassie staining. Pure Affi-
mer-NP was then concentrated using centrifugal concentrators, as above.
For complex purification, concentrated Affimer-NP and CCHFV NP were mixed and
injected onto an equilibrated HiLoad 26/600 Superdex 75 pg (GE Healthcare) column using
an Akta prime at 0.5 mL/min. Size exclusion chromatography was performed at 4˚C and 3 mL
fractions were collected. Purity of the complex was analyzed by SDS-PAGE followed by Coo-
massie staining and then concentrated using Amicon Ultra 15 Ultracel 10 kDa MWCO Regen-
erated Cellulose concentrators.
Crystallization, Data Collection, and Refinement
Affimer-NP/CCHFV NP complex was concentrated to 10 mg/mL and crystallized at RT from
a 1:1 ratio of protein:reservoir solution (0.2 M NH4CH3CO2, 0.1 M CH3COONa 4.6 pH, 30%
PEG 4K). For vitrification, crystals were transferred to mother liquor containing 25% glycerol.
Diffraction data were collected at DLS beamline I04, and structure of the complex solved at
2.84 Å by molecular replacement using published models of the Adhiron scaffold (PDB:4n6u)
and CCHFV NP (PDB:4akl) with Phaser. Interface residues between Affimer-NP and CCHFV
NP were predicted using Chimera and PDBePISA.
Fluorescence anisotropy
For direct binding assays, CCHFV NP was serially-diluted using RNA-binding buffer (100
mM NaCl, 10 mM tris-HCl 7.5, 0.01% Triton X-100) in a black 384-well optiplate (Perkin-
Elmer). 30-Fluorescein RNAs were added, obtaining a final concentration of 2.5 nM FI-RNA/
well. For competition assays, Affimers were serially-diluted using RNA-binding buffer. 30-Fl
RNAs mixed with CCHFV NP were added to each well, obtaining a final concentration of 230
nM CCHFV NP and 2.5 nM FI-RNA per well. Reactions were incubated at RT for 30 min and
fluorescence polarization measured using a Spark 10M microplate reader (Tecan) with excita-
tion and emission filters at 485 nm and 535 nm, respectively. Nonlinear regression curves
were fitted using GraphPad to obtain KD and IC50 values.
CCHFV mini-genome
Detailed plasmid sequences are available upon request. Briefly, the CCHFV S-segment repli-
con was generated using strain Baghdad-12 (GenBank: AJ538196.1) as reference. The S-seg-
ment cDNA was incorporated within a plasmid vector flanked by bacteriophage T7 RNA
polymerase promoter (T7POL) and hepatitis delta virus ribozyme, and orientated for expres-
sion of viral sense RNA. The S-segment NP open reading frame (ORF) was replaced by a
cDNA representing the eGFP ORF to generate pC-SsegUTRs-GFP. Support plasmids (pC-NP
and pC-L) expressing Baghdad-12 CCHFV NP and L proteins were generated by inserting the
corresponding cDNA sequences (GeneBank: CAD61342.1 and AY947890.1) downstream of
T7POL and a cDNA representing the encephalomyocarditis virus (ECMV) internal ribosome
entry site. The Affimer-NP ORF fused to the RFP ORF was subcloned into a protein expres-
sion vector behind the CMV promoter (pMAX-Affimer-NP-RFP). A negative control plasmid
containing the ORF of a yeast SUMO-specific Affimer fused to RFP was also generated
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(pMAX-Affimer-YS-RFP). Sub-confluent BSRT7 cells in a 12-well plate were transfected with
450 ng pC-L, 150 ng pC-NP, 150 ng pC-SsegUTRs-GFP and increasing concentrations of
pMAX-Affimer-NP-RFP or pMAX-Affimer-YS-RFP using TransIT-LT1 (Mirus Bio) as trans-
fection reagent in a 2.5:1 ratio of TransIT-LT1:DNA (μL:μg). Green/red fluorescence were
quantified using an IncuCyte Live-Cell analysis system with IncuCyte ZOOM software 2018.
ELISA for detection of CCHFV NP
High-binding 96-well plates (Sigma-Aldrich) were coated overnight with 1 μg of Affimer-NP
in 100 μL carbonate buffer, pH 9.6. Plates were blocked with ELISA stabilizing solution (Sur-
modics) for 1h. After washing with PBS-T, plates were incubated with 100 μL of spiked sera
for 1h, followed by primary antibody (anti-CCHFV NP IgGs). Plates were washed and incu-
bated with 100 μL of goat anti-rabbit IgGs-HRP (Sigma-Aldrich) for 1h, followed by 100 μL of
3,3’,5,5’-tetramethylbenzidine (TMB) Enhanced K-Blue substrate (Neogen) for 10 min. Reac-
tion was stopped with 100 μL of 0.5 M sulfuric acid and absorbance (450 nm) measured with a
SpectraMax M5 (Molecular Devices) plate reader.
Lateral flow assay for detection of CCHFV NP
Functionalization of beads. For the test line, anti-CCHFV NP IgGs were conjugated to
300 nm red latex particles (Ikerlat) and for the control line, BSA-biotin was conjugated to 260
nm blue latex particles (Ikerlat). Beads were washed in MES 10 mM pH 6 and their size was
measured by dynamic light scattering (DLS) using a Zetasizer Nano S system (Malvern). Beads
were activated using EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride)
and NHS (N-hydroxysuccinimide) and added to the protein of interest. After incubation for 2
h, 500 mM imidazole was added, and beads were washed with 0.1% Tween-20. Blue and red
functionalized beads were mixed, diluted in tris-HCl 25 mM, pH 9.5 and dispensed onto a
rayon conjugate pad 25-mm (Operon) using a Matrix 1600 dispensing module (Kinematic
Automation). Conjugate pad was incubated 30 min in a MMUFE 500 oven (Memmert) at
45˚C.
Membrane dispensation. For the test line, Affimer-NP was diluted in tris-HCl 20 mM
pH 8.5, containing 5.0% sucrose and 0.095% sodium azide. Anti-biotin IgG for the control line
was diluted (1 mg/mL) in the same buffer (pH 7.5). Both reagents were dispensed in two paral-
lel lines on nitrocellulose membrane at 1 μL/cm. Dispensed membranes were dried for 5 min
at 45˚C.
LFA assembly. A master card was assembled on a 72-mm backing card (Kenosha) as fol-
lows: HiFlow Plus Nitrocellulose Membrane (HF120) (Millipore), the conjugate pad (Operon)
and a 25-mm absorbent pad (Ahlstrom) were pasted and covered with a 65-mm transparent
adhesive film (Lohmann). The master card was cut to 4.2-mm width strips using a Matrix
2360 machine (Kinematic Automation).
LFA sample testing. Sample (20 μL) and buffer (100 μL) were added sequentially, and
results annotated after 10 min., with quantification using a ESE Quant Lateral Flow reader
(Qiagen) and Lateral Flow Studio Software.
Results
Selection of CCHFV NP-specific Affimers
The goal of this study was to identify, purify and characterize Affimer binding reagents specific
for CCHFV NP, and to evaluate their potential for use as specific binding molecules in diag-
nostic tools as well as in interfering with critical CCHFV activities. Affimer affinity reagents
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are a class of non-antibody binding proteins based on a phytocystatin consensus sequence that
scaffolds two variable peptide regions that represent target recognition sites. They can be
selected against diverse targets providing high-affinity binding molecules that mimic the molec-
ular recognition of antibodies. Large bacteriophage (‘phage display) libraries are used for their
selection and they can be produced easily and economically by recombinant means in bacterial
expression systems [26,27]. Recombinant CCHFV NP was used as target molecule for Affimer
screening, as previously described [25]. Twenty-four Affimers were isolated and sequenced
resulting in 7 unique binders (Affimers 1, 5, 6, 8, 9, 22 and 24, S1A Fig). After bacterial expres-
sion and purification using Ni2+-NTA affinity chromatography, Affimers were biotinylated
using a biotin maleimide moiety, as was a myoglobin-specific Affimer (Affimer-myo), as a nega-
tive control. Presence of biotin was analyzed by ELISA using streptavidin-HRP (S1B Fig).
Affimer-NP binds specifically to CCHFV NP
The ability of the Affimers to bind CCHFV NP was first assessed by pull-down affinity-precipi-
tation (AP) assays. Briefly, streptavidin-conjugated beads were coated with the 8 biotinylated
Affimers and incubated with CCHFV NP. After washing, samples were analyzed by
SDS-PAGE and western blotting using anti-CCHFV NP IgGs and an anti-his-tag antibody.
Only Affimer-1 showed clear binding to CCHFV NP. All others showed no binding, including
the negative control Affimer (Affimer-myo), and the beads-only control (Fig 1A).
Affimer-1 (named Affimer-NP) was chosen as the CCHFV NP binder of interest. To deter-
mine the specificity of Affimer-NP for CCHFV NP, additional AP assays were performed using
CCHFV NP and NP from the closely-related Hazara virus (HAZV) as target molecules. HAZV
forms part of the CCHFV serogroup [28], their NPs share 59% amino acid identity [24] and
their crystal structures very closely superpose with an RMSD = 0.70 Å [24] within the respective
globular domains. HAZV NP was produced, and AP assays were analyzed by western blotting
using the primary antibodies described above (S2 Fig). Affimer-NP showed binding to CCHFV
NP but not to HAZV NP, and the negative control Affimer-myo showed no binding to either
NP (Fig 1B). These results demonstrate that Affimer-NP selectively recognizes CCHFV NP,
showing no cross-reactivity with HAZV NP, despite their close structural similarity.
Affimer-NP binds CCHFV NP with high affinity
To determine the binding kinetics and affinity of Affimer-NP for CCHFV NP, surface plas-
mon resonance (SPR) was performed, along with Affimer-myo and HAZV NP as negative
controls. Different cells of a streptavidin sensor chip were coated with biotinylated Affimer-
NP and Affimer-myo, and ten-fold dilutions of CCHFV or HAZV NP were injected into each
cell. CCHFV NP sensograms showed binding to Affimer-NP but not to Affimer-myo (Fig 1C)
and conversely, HAZV NP sensograms showed no binding to either Affimer-NP nor Affimer-
myo (Fig 1D). CCHFV NP sensograms were fitted to a Langmuir 1:1 binding model and
steady state affinity models. The most accurate fitting corresponded to the 10 nM dilution (S3
Fig), presenting the lowest Chi2 values relative to the response units of the sensogram (Chi2 =
0.104). The fitted curve reveals a low nanomolar KD (KD = 5.69 nM), demonstrating a high
affinity interaction between Affimer-NP and CCHFV NP with a fast rate association (Kon =
1.17 x 106 M-1 s-1) and a slow rate dissociation (Koff = 6.67 x 10
−3 s-1).
Secondary structure and thermostability of the Affimer-NP/CCHFV NP
complex
To better understand the thermal stability of Affimer NP both alone and in complex with
CCHFV NP, we next used circular dichroism (CD) to analyze the secondary structure of
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Affimer-NP, CCHFV NP and a 1:1 molar mix of both, in response to changing temperature.
CD spectra were measured between 190–260 nm at temperatures between 20˚C to 90˚C and
secondary structure content was predicted using the online prediction tool BeStSel [29]. Affi-
mer-NP spectra presented a single minimum at 218 nm, indicating a predominance of beta-
sheets (Fig 2A), in agreement with the secondary structure prediction software (S4A Fig), and
consistent with published scaffold structures [26] (PDB:4n6u, Fig 2A). The melting tempera-
ture (Tm) obtained for Affimer-NP was 74.37˚C (Fig 2D), also previously observed [26].
CCHFV NP spectra showed two minima at 208 and 222 nm (Fig 2B), which indicates predom-
inance of alpha-helices, also in concordance with both secondary structure prediction (S4B
Fig) and published CCHFV NP structures [7] (PDB:4akl, Fig 2B). The Tm obtained for
CCHFV NP was 31.74ºC (Fig 2E), also in agreement with published data [24]. The CD spectra
of the CCHFV NP/Affimer-NP mixture showed two minima at 208 and 222 nm, indicating a
predominance of alpha-helices (Fig 2C; S4C Fig) as expected due to a greater global contribu-
tion of CCHFV NP alpha-helices relative to Affimer-NP beta-sheets. The Tm obtained for the
mixture (43.35˚C, Fig 2F) was higher than the Tm of CCHFV NP alone, indicating that Affi-
mer-NP delayed the melting of alpha-helical structures, predominantly corresponding to
CCHFV NP (S4D Fig). Taken together, these CD analyses suggest that Affimer-NP induces
thermostabilization of CCHFV NP.
Fig 1. Specificity and affinity of Affimer-NP. (A) Western blot analysis of a pull-down experiment using Affimers as capture
molecules and CCHFV NP as target. (B) Western blot analysis of a pull-down experiment using either HAZV or CCHFV NP as
target. (C, D) SPR analysis of binding between Affimers and ten-fold dilutions of CCHFV (C) or HAZV NP (D).
https://doi.org/10.1371/journal.pntd.0008364.g001
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Affimer-NP competes with the RNA-binding of CCHFV NP
We next examined whether Affimer-NP may hold the potential to disrupt native CCHFV NP
functions, one of which is RNA binding, required during the CCHFV replication cycle for
genome encapsidation. The RNA binding ability of CCHFV NP was assessed using fluores-
cence anisotropy (FA), which measures the tumbling rate of a fluorescently-labelled RNA in
solution that is reduced upon interaction with a ligand, in this case CCHFV NP. FA assays
were performed to assess whether Affimer-NP interferes with the RNA-binding function of
CCHFV NP using two fluorescein-labelled synthetic RNA oligos (27 and 48-mer RNAs). After
Fig 2. CD analyses of Affimer-NP, CCHFV NP and Affimer-NP/CCHFV NP complex. (A, B, C) Curves
representing ellipticity across the far UV spectra of CCHFV NP (A), Affimer-NP (B) or a 1:1 mixture of both (C) at
20ºC-90ºC. Crystal structure of Affimer scaffold (PDB:4n6u) is represented in orange and CCHFV NP (PDB:4akl) in
blue. (D, E, F) Curves representing folded/unfolded fractions and melting temperatures (Tm) of Affimer-NP (D),
CCHFV NP (E) and their mixture (F).
https://doi.org/10.1371/journal.pntd.0008364.g002
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analyzing the RNA-binding affinity of CCHFV NP to the RNAs in vitro and defining the KD of
the interaction (KD 27mer = 0.190 μM ± 0.0062, KD 48mer = 0.230 μM ± 0.008, S5 Fig), a compet-
itive assay was performed using Affimer-NP and the negative control Affimer-myo. Affimer-
NP showed interference in the RNA-binding of CCHFV NP with IC50 values of IC50 27mer =
0.197 ± 0.0084 μM and IC50 48mer = 0.167 ± 0.0046 μM, respectively (Fig 3A and 3B), whereas
in contrast, the negative control Affimer-myo, showed no such interference. Taken together,
these results show that Affimer-NP specifically-inhibits the RNA binding ability of CCHFV
NP.
Affimer-NP interferes with CCHFV gene expression
The competition of Affimer-NP in the RNA-binding activity of CCHFV NP, which is critical
for formation of CCHFV RNA segments, raised the possibility that Affimer-NP would also
inhibit CCHFV gene expression. To test this hypothesis, a CCHFV mini-genome system that
uses eGFP as reporter of gene expression was established. Plasmids encoding CCHFV mini-
genome components were transfected into mammalian-origin BSRT7 cells along with differ-
ent concentrations of plasmids (50, 100, 250, 500 and 750 ng) expressing Affimer-NP ORF
fused to RFP (pMAX-AF-NP-RFP) or a negative control Affimer in which the Affimer-NP
sequence was exchanged for a yeast SUMO-specific Affimer (pMAX-AF-YS-RFP). In vivo
green and red fluorescence signals were monitored using an IncuCyte live cell imaging system,
corresponding to CCHFV specific gene expression and the Affimers, respectively. Co-transfec-
tion of the replicon with 750 ng of the control Affimer-YS-RFP plasmid resulted in unchanged
eGFP reporter signal (Fig 3C and 3D), whereas increasing amounts of Affimer-NP-RFP corre-
lated with a statistically significant decrease in reporter signal (Fig 3D and 3E). These results
illustrate a specific and dose-dependent interference of Affimer-NP in CCHFV-specific gene
expression.
Tertiary structure analysis of the Affimer-NP/CCHFV NP complex
To further characterize the interaction between Affimer-NP and CCHFV NP and determine
the molecular basis for the interference of Affimer-NP with CCHFV NP RNA-binding and
gene expression functions, we solved the high-resolution crystal structure of the complex. Due
to the flexibility of the terminal 8xhis and the possibility that the terminal cysteines may form
disulphide bonds, Affimer-NP was expressed with N-terminal 6xhis and SUMO Smt3 tags.
After initial purification using affinity chromatography, the 6xhis-yeast SUMO tags were
removed using ULP1 SUMO protease, and Affimer-NP was further purified using sequential
affinity and size exclusion chromatography steps (S6 Fig).
Affimer-NP and CCHFV NP were mixed and the complex purified by size exclusion chro-
matography (S6 Fig). The complex was concentrated and crystallized, and the structure was
solved at 2.84 Å resolution using Phaser and PDB models 4n6u (Affimer scaffold, Fig 2A) and
4akl (CCHFV NP, Fig 2B) for molecular replacement. Two Affimer-NP/CCHFV NP com-
plexes were elucidated per asymmetric unit. The structure shows the variable loops of Affimer-
NP bound to the globular domain of CCHFV NP, mainly interacting with the residues Q329,
F330, F332, E333, K336, R339, K343, A347, T351, N399, D402 and L405 (Fig 4B and 4C).
As previously published structures show, CCHFV NP contains two major domains: a glob-
ular core and an extended arm [7–9]. Although no crystal structure of CCHFV NP in complex
with RNA has been solved to date, analysis of its electrostatic surface potential reveals a contin-
uous positively charged region, likely the binding site for RNA, comprising residues R45, K72,
S149, H197, K222, R225, K237, Q303, K336, R339, K342, K343, K345, R372, and K462 [30]
(highlighted in blue in Fig 4A–4C). The variable loops of Affimer-NP show interaction
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contacts with three of these residues (K336, R339 and K343), plausibly explaining the observed
disruption of the NP-RNA interaction, described above.
Structural analyses of CCHFV NP also suggest that its oligomerization plays a critical role
in RNA-binding, and together these two activities are required for RNP formation and thus
gene expression. CCHFV NP exists as a monomer in the absence of RNA, but different oligo-
meric forms have been described when bound to RNA of the expression host. The interaction
between monomers involves residues 320–354 within the head domain of one molecule and
residues 210–219 and 260–272 of the arm of the adjacent molecule [9] (highlighted in pink in
Fig 4A–4C). The residues of the globular domain that interact with the variable loops of Affi-
mer-NP all lie between NP residues 320–354, suggesting a potential interference of Affimer-
NP in CCHFV NP oligomerization. As both oligomerization and RNA-binding are required
for assembly of functional CCHFV RNPs, the location of the Affimer-NP binding site also
offers a likely explanation for its ability to disrupt CCHFV mini-genome activity.
Fig 3. Inhibitory effects of Affimer-NP. (A, B) FA analysis of RNA-binding interference of Affimer-NP using 27mer
(A) or 48mer (B) RNA molecules. Top-right graphs represent negative control experiments using Affimer-Myo. (C)
IncuCyte pictures taken 72h post-co-transfection of CCHFV mini-genome components plus 750 ng of Affimer-
NP-RFP, Affimer-YS-RFP or no Affimer (C-). GFP signal corresponds to CCHFV-specific gene expression and RFP
signal corresponds to Affimers-RFP. Scale bar = 300 μm. (D) GFP reporter signal 72h post-co-transfection of CCHFV
mini-genome components with 750 ng of Affimer-NP, Affimer-YS or no Affimer (C-). (E) GFP and RFP signal 72h
post-co-transfection of CCHFV mini-genome components with different amounts of Affimer-NP-RFP. Data are
presented as mean ±SD (n = 3). Statistical analysis was performed using a paired t-test (ns = non-significant, ��� =
p<0.001).
https://doi.org/10.1371/journal.pntd.0008364.g003
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The specificity of Affimer-NP for CCHFV NP, showing no cross-reactivity with HAZV NP,
may also be explained by this crystal structure. Of the 12 CCHFV NP residues that interact
with Affimer-NP (highlighted in orange in Fig 4D and 4E), 3 are not conserved in the HAZV
NP (N399, L405, K336, highlighted in blue in Fig 4D and 4E), suggesting these changes are
likely responsible for the differential recognition of CCHFV and HAZV NPs.
Validation of Affimer-NP as recognition molecule in a sandwich ELISA
The high affinity, specificity and binding kinetics of Affimer-NP for CCHFV NP suggested it
could act as a recognition molecule for development of in vitro diagnostic tests. First, Affimer-
NP was tested as a capture molecule in sandwich ELISA. Briefly, 96-well plates were coated
with Affimer-NP and incubated with different concentrations of CCHFV NP diluted in animal
or human sera. As negative controls, other bunyaviral NPs namely HAZV, Rift Valley fever
virus (RVFV) and Schmallenberg virus (SBV) were also tested. Anti-CCHFV NP IgGs were
used as primary recognition molecule, and a secondary anti-rabbit antibody labelled with HRP
was used to provide a colorimetric output (Fig 5A). Concentration of Affimer-NP, primary
and secondary antibodies were optimized to obtain the best signal-to-background ratios.
Fig 4. Tertiary structure of Affimer-NP/CCHFV NP complex. (A) Crystal structure of CCHFV NP (PDB:4akl).
Residues involved in RNA-binding, monomer-monomer interactions, or both are highlighted in blue, pink and
purple, respectively. (B) Crystal structure of Affimer-NP (represented in orange) bound to CCHFV NP. (C) Close-up
of Affimer-NP/CCHFV NP interaction. (D) Alignment of CCHFV NP (residues 329–407, PDB:4akl) and HAZV NP
(PDB:4xze). NP residues comprising the Affimer-NP variable loop contacts are highlighted in orange, when conserved
in both CCHFV and HAZV NPs, or in cyan if not. (E) Close-up of CCHFV NP residues involved in the interaction
with Affimer-NP loops. Non-conserved residues (cyan) are labeled.
https://doi.org/10.1371/journal.pntd.0008364.g004
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The Affimer-NP based sandwich ELISA detected CCHFV NP in spiked sera from horse,
goat, sheep, cow and human sources. The limit of detection (LOD) varied for the different sera
samples, ranging from 31.25 ng/well (sheep) to less than 3.9 ng/well (horse). No cross-reactiv-
ity was shown when testing the negative control NPs of HAZV, RVFV and SBV (Fig 5B–5F).
Validation of Affimer-NP as recognition molecule in a lateral flow assay
Next, we tested the suitability of Affimer-NP for development of a lateral flow assay (LFA) (Fig
6). Briefly, red latex beads were coated with anti-CCHFV NP IgGs and Affimer-NP was depos-
ited on the LFA membrane. Concentration of antibody and Affimer-NP were optimized to
Fig 5. Sandwich ELISA for the detection of CCHFV NP. (A) Affimer-NP was used as capture molecule for CCHFV NP in
spiked sera. Anti-CCHFV NP IgGs were used as detection molecule. Anti-rabbit goat polyclonal IgGs labelled with HRP were
used to develop the colorimetric output using TMB as substrate. (B, C, D, E, F) ELISA results testing sera from animals (B-E)
or human (F) spiked with CCHFV, HAZV, SBV or RVFV NPs.
https://doi.org/10.1371/journal.pntd.0008364.g005
PLOS NEGLECTED TROPICAL DISEASES Inhibition of viral replication and diagnostic applications of a CCHFV NP specific Affimer
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008364 June 3, 2020 13 / 20
obtain the strongest signal in the test line. For the control line, BSA-biotin was conjugated to
blue latex particles and an anti-biotin IgG monoclonal antibody was dispensed in the mem-
brane. The size of the latex beads was monitored by dynamic light scattering to avoid use of
aggregated particles (S7 Fig). Spiked samples were prepared using different concentrations of
CCHFV NP diluted in either animal or human sera, with samples applied to strips followed by
addition of running buffer. NPs of other bunyaviruses (HAZV, RVFV and SBV) were also
tested as negative controls. The strength of the control line was evaluated by eye (Fig 7C) and
quantified using an ESE Quant Lateral Flow reader (Fig 7A and 7B).
The Affimer-NP based LFA detected recombinant CCHFV NP in spiked sera from horse,
goat, sheep, cow and human. No cross-reactivity was shown when testing these sera spiked
with negative control NPs from other bunyaviruses (Fig 6A–6C). At least 10 negative field sera
samples from each animal and from humans were tested, and none gave false positives, dem-
onstrating a 100% specificity of the LFAs for CCHFV NP under these conditions.
The LOD of both assays was compared using horse sera spiked with different concentra-
tions of CCHFV NP (Fig 7D). The sandwich ELISA detected down to 1.5 ng of recombinant
CCHFV NP/well (0.015 μg/mL), whereas the LOD of CCHFV NP by LFA was 15 ng/strip
(0.75 μg/mL).
Discussion
CCHFV-mediated disease is an important public health issue and an urgent need for acceler-
ated research in its diagnosis and treatment has been declared [11]. Here, we generated and
Fig 6. Development of a LFA for the detection of CCHFV NP using Affimer-NP as detection molecule. (A, B)
Schematic of the LFA. Affimer-NP was used as detection molecule on the membrane of the LFA strip and anti-
CCHFV NP polyclonal rabbit IgGs were used as capture antibody for the coating of red latex beads. Control anti-
biotin mouse IgGs were used for the control line in the membrane together with biotin-BSA for the coating of blue
latex beads. If a CCHFV NP spiked sample (A) is applied to the strip, the CCHFV NP binds to the antibody in the red
beads and it is subsequently captured by the Affimer-NP in the membrane, resulting in a red test line. In the case of a
negative sample (B), there is no CCHFV NP present and the red latex beads migrate until the end of the strip, resulting
in an uncolored test line. In both cases, the BSA-biotin coated blue latex beads bind to the anti-biotin mouse IgG on
the membrane, resulting in a blue control line.
https://doi.org/10.1371/journal.pntd.0008364.g006
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characterised a novel CCHFV NP specific binding molecule, Affimer-NP, that exhibited an
inhibitory effect in CCHFV gene expression and possesses potential for use in diagnostic
applications.
Affimers for more than 100 targets have been previously described in the literature with
high specificity and low nanomolar affinities [26]. Likewise, Affimer-NP presents high speci-
ficity for CCHFV NP, lacking cross-reactivity with its close homologue HAZV NP, and exhib-
iting high affinity with a nanomolar KD.
The secondary structure and melting temperatures obtained for Affimer-NP and CCHFV
NP are consistent with previously published data [7,24,26]. The high Tm of Affimer-NP indi-
cates high thermostability, which is a characteristic feature of Affimer reagents [26]. The mix-
ture of Affimer-NP and CCHFV NP presented a higher Tm than CCHFV NP, suggesting that
the binding of Affimer-NP delays the melting of alpha-helical structures in the nucleoprotein
inducing its thermostabilization.
A specific interference of Affimer-NP in the RNA-binding function of CCHFV NP and
CCHFV gene expression was demonstrated in the context of a newly-developed CCHFV
mini-genome system. While this system lacks the authenticity of a CCHFV infection, it allows
Fig 7. Affimer-NP based LFA results and comparison with ELISA. (A) LFA positive line intensity measured after applying animal
sera spiked with CCHFV, HAZV or SBV NP (120 ng NP/strip). (B) Histogram representation of data in (A). (C) LFAs 10 min after
application of horse sera samples spiked with CCHFV, HAZV, SBV or RVFV NP. (D) Comparison of performance between ELISA
and LFAs using horse sera spiked with CCHFV NP. Primary axes correspond to LFAs and secondary axes to ELISA. Limits of
detection are highlighted with an asterisk.
https://doi.org/10.1371/journal.pntd.0008364.g007
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specific examination of the effect of Affimer-NP at the stage of RNA synthesis, highly relevant
to its NP-binding properties. While further investigations of Affimer-NP inhibitory properties
need to be performed using infectious virus and animal models, our findings suggest a poten-
tial antiviral effect of this molecule. The antiviral drug ribavirin is the only currently available
therapeutic agent for the treatment of CCHFV infections, but its mechanism of action remains
to be elucidated and case–control studies have not been conducted to date [23]. The use of
Affimers for therapeutic purposes has not been yet fully investigated, but their small size, and
high stability and solubility make them attractive candidates for therapeutic applications [26].
A better understanding of the Affimer-NP/CCHFV NP interaction was achieved by the elu-
cidation of the crystal structure of the complex. The variable loops of Affimer-NP bind to the
globular domain of CCHFV NP with interaction sites including residues previously predicted
to participate in both NP-RNA interactions and oligomerization, suggesting a possible inter-
ference of Affimer-NP in these two fundamental NP functions. The specificity of Affimer-NP
for CCHFV NP and the lack of cross-reactivity with HAZV NP can also be explained by the
crystal structure of the complex. Affimers have shown high selectivity in previous studies,
being able to differentiate even between analogues of small molecules [27]. From the predomi-
nant 12 residues involved in the interaction contacts between Affimer-NP and CCHFV NP,
only 3 are not conserved in HAZV NP, seemingly being enough to prevent its recognition by
Affimer-NP.
The high affinity, specificity and stability of Affimer-NP suggested it represents a promising
candidate for detection of CCHFV NP in patient sera as a diagnostic assay. Accurate diagnosis
of CCHFV can be achieved when molecular methods are combined with antibody detection in
serial serum samples [31], but the performance of these techniques is not always suitable in
remote areas or in low-resource settings, creating the need of a point-of-care test for early diag-
nosis. Affimer-NP showed an efficient performance as a capture molecule in a sandwich
ELISA format, detecting down to 1.5 ng of recombinant CCHFV NP per 100 μL of human and
animal sera. A previous study has shown that an antibody-based antigen-capture ELISA with a
LOD of 2 ng of recombinant CCHFV NP per 100 μL was suitable for the detection of native
CCHFV in acute sera of CCHFV-infected patients [32]. According to these observations, the
Affimer-NP based sandwich ELISA has a similar LOD to an antibody-based ELISA, and conse-
quently is likely to be capable of detecting native CCHFV NP in acute patient samples, but this
important validation remains to be experimentally demonstrated in future work.
The Affimer-NP based LFAs presented in this study require minimal specimen processing,
have time to results of minutes and are suitable for field testing and low-infrastructure settings.
The high thermostability of Affimer-NP allows its immobilization into the LFA membrane,
which involves a baking step at 45˚C, and suggests such devices will be robust in the field. This
is a remarkable advantage of Affimer reagents, particularly relevant in low-resource settings
where refrigerated storage of diagnostic tests may not be possible [33]. The use of Affimers as
detection molecules also provides additional benefits due to their low production cost and
consistent batch uniformity. In our hands, these tests present 100% specificity for CCHFV NP
and their LOD is 15 ng of recombinant CCHFV NP/strip. There are no previous studies
describing the LOD needed for LFA devices to successfully detect CCHFV NP in acute patient
samples, nor reference antigen preparation standards for hemorrhagic fever viral NPs [34].
But different types of point-of-care diagnostic tests have shown the ability to detect hemor-
rhagic fever viral NPs in virus isolates and patient samples, such is the case for Lassa virus [35],
Ebola virus [36] or RVFV [37]. In order to determine if the sensitivity of our current device is
sufficient to detect CCHFV NP in real patient samples, it will need to be experimentally tested
and optimized using patient samples under high-level biosafety containment. Nonetheless, the
results presented in this study serve as proof of concept for the use of Affimers in LFAs and
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represent the first prototype point-of-care diagnostic test for the detection of recombinant
CCHFV NP in sera described to date. These findings represent a possible starting point for the
future development of Affimer-based diagnostic assays for the detection of CCHFV NP, con-
tributing to the preparedness for potential future outbreak scenarios.
Supporting information
S1 Fig. Anti-CCHFV NP Affimer hits. (A) Alignment of the Affimer ORF amino acid
sequences corresponding to the 7 Affimer hits obtained in the CCHFV NP Affimer screening
after their subcloning into a pET11a vector. Variable loops (Loop 1 and Loop 2) and the C-ter-
minal cysteine and 8xHis tail are indicated. (B) Different amounts (1, 0.1 or 0.01 μL) of bioti-
nylated Affimers (0.5 mg/mL) were incubated with streptavidin-HRP and TMB.
(TIF)
S2 Fig. Anti-CCHFV NP IgGs cross-react with HAZV NP and vice versa. (A) SDS-PAGE
and western blot analysis of recombinant CCHFV NP and HAZV NP using anti-CCHFV NP
as primary antibody. (B) SDS-PAGE and western blot analysis of recombinant CCHFV NP
and HAZV NP using anti-HAZV NP as primary antibody.
(TIF)
S3 Fig. SPR data fitting. (A) Fitting of the SPR sensogram corresponding to the binding of
CCHFV NP (10 nM) and Affimer-NP to a Lagmuir 1:1 binding model. (B) Association (kon),
dissociation (koff) and affinity (KD) constants and Chi
2 value obtained from the fit curve in
(A).
(TIF)
S4 Fig. Prediction of secondary structure elements. (A, B, C) Percentage of alpha-helices,
beta-sheets, turns and other secondary structure elements of Affimer-NP (A), CCHFV NP (B)
and the complex (C) at 20˚C. (D) Normalized predicted alpha-helical content of CCHFV NP
and Affimer-NP/CCHFV NP complex at different temperatures (20˚C to 90˚C).
(TIF)
S5 Fig. Direct binding fluorescence anisotropy analyses. (A, B) RNA-binding of CCHFV NP
to 27mer (A) or 48mer (B) synthetic RNA molecules. Data in (A) and (B) are presented as
mean ±SD (n = 3 replicates) and are fitted to a nonlinear regression curve.
(TIF)
S6 Fig. Purification of native Affimer-NP and Affimer-NP/CCHFV NP complex. (A)
SDS-PAGE and Coomassie staining analysis of the different fractions obtained during the first
Ni2+-NTA affinity chromatography. (B) SDS-PAGE and Coomassie staining analysis of the
different fractions obtained during the cleavage of the 6xhis-SUMO tag and a second Ni2+
-NTA affinity chromatography. (C) Chromatogram of the size exclusion chromatography of
Affimer-NP after the second Ni2+-NTA affinity chromatography. (D) SDS-PAGE analysis and
Coomassie staining of the size exclusion chromatography fractions containing native Affimer-
NP. (E) Chromatogram of the size exclusion chromatography of Affimer-NP/CCHFV NP
complex. (F) SDS-PAGE analysis and Coomassie staining of the size exclusion chromatogra-
phy fractions containing the complex.
(TIF)
S7 Fig. Dynamic light scattering analyses of latex beads. Size distribution of beads functiona-
lized with anti-CCHFV NP IgGs (black) and a mix of latex beads functionalized with anti-
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CCHFV NP IgGs and control biotin-BSA beads (grey).
(TIF)
S1 Table. X-Ray Crystallography data collection and refinement statistics.
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